Boule Diagnostics publishes the interim report Q2 2020 on July 17, 2020 at 08.00 CET

Boule Diagnostics AB will bring the publishing of the interim report for the period January–June 2020 forward to 08:00, Friday, July 17^th, 2020. The previously communicated publishing date was August 17^th. The interim report will be accessible at http://www.boule.com when published.  

Following the publication, Boule will hold a conference call at 15:30 for media and investors. CEO Jesper Söderqvist and CFO Christina Rubenhag will present and comment on the interim report. After the presentation there will be time for audience questions. The presentation will be held in English and can be accessed as described below.

Time:                                             15:30 CET, Friday, July 17^th, 2020

Telephone number:                    +46 (0)8-744 77 22

Code:                                            1212

For further information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)705-46 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

The information was submitted for publication, through the agency of the contact person set out above,
at 08.30 CET on July 10, 2020.

Release